The emerging role of miRNAs for the radiation treatment of pancreatic cancer.
Cancers 12:3703 (2020)
Today, pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide with a five-year overall survival rate of less than 7%. Only 15–20% of patients are eligible for curative intent surgery at the time of diagnosis. Therefore, neoadjuvant treatment regimens have been introduced in order to downsize the tumor by chemotherapy and radiotherapy. To further increase the efficacy of radiotherapy, novel molecular biomarkers are urgently needed to define the subgroup of pancreatic cancer patients who would benefit most from radiotherapy. MicroRNAs (miRNAs) could have the potential to serve as novel predictive and prognostic biomarkers in patients with pancreatic cancer. In the present article, the role of miRNAs as blood biomarkers, which are associated with either radioresistance or radiation-induced changes of miRNAs in pancreatic cancer, is discussed. Furthermore, the manuscript provides own data of miRNAs identified in a pancreatic cancer mouse model as well as radiation-induced miRNA changes in the plasma of tumor-bearing mice.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Biomarker ; Mirna ; Pancreatic Cancer ; Personalized Medicine ; Radioresistance ; Radiotherapy ; Target; Cell Lung-cancer; Microrna Expression; Breast-cancer; Increases Radiosensitivity; Promotes Proliferation; Ductal Adenocarcinoma; Diagnostic Biomarkers; Potential Biomarker; Carcinoma-cells; Down-regulation
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2020
Prepublished im Jahr
HGF-Berichtsjahr
2020
ISSN (print) / ISBN
2072-6694
e-ISSN
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 12,
Heft: 12,
Seiten: ,
Artikelnummer: 3703
Supplement: ,
Reihe
Verlag
MDPI
Verlagsort
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Radiation Sciences
PSP-Element(e)
G-501300-001
Förderungen
KKF, Medical Faculty of the Technical University of Munich (TUM)
Helmholtz Zentrum Munchen
German Consortium for Translational Cancer Research
Hans und Klementia Langmatz Stiftung
Medical Faculty of the Technical University of Munich (TUM)
Deutsche Forschungsgemeinschaft (DFG, German Research foundation)
"Translational & Clinical Projects", Helmholtz Zentrum Munchen
Munich/TUM site
Medical Faculty of TUM
Copyright
Erfassungsdatum
2021-02-05